Melbourne, May 12, 2008 (ABN Newswire) - Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced positive results of a clinical trial that achieved all its objectives demonstrating that 3% SPL7013 Gel (VivaGel(R)) was safe and well-tolerated in sexually abstinent women when administered vaginally, twice daily for 14 days.
